Harrow, Inc.
HROW Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$28.95
KIRA · Stoqly’s AI analyst, in plain words
- Harrow, Inc. had $272M of revenue in fiscal 2025, up 36.4% on the year before. Over five years, revenue changed +41.0% a year on average.
- Its operating margin was 11.2%, up 6.8 pts: of every 100 in sales, about 11 is left after running the business.
- Harrow, Inc. lost $5.1M in fiscal 2025.
- Free cash flow was $43.0M in fiscal 2025, 15.8% of revenue.
- Harrow, Inc. owes $177M more than it holds in cash, about 5.5 years of operating profit.
Market cap
$1.1B
P/E
—
Revenue
$272M
Net income
−$5.1M
Free cash flow
$43.0M
Operating margin
11.2%
Harrow, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+36.4%
Yes. Sales grew 36.4% last year.
Does it make a profit?
−1.9%
No. It lost money last year.
Does profit turn into cash?
15.8%
Yes. 15.8% of sales ends up as free cash.
Is debt under control?
5.5x
Heavy. Repaying its debt would take 5.5 years of operating profit.
How healthy are the accounts?
6 / 9
Mixed. It passes 6 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Harrow, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 2, 2026
- Legal name
- HARROW, INC.
- CIK
- 0001360214
Harrow, Inc. · HROW
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $72.5M | $88.6M | $130M | $200M | $272M |
| Revenue growth | 48.3% | 22.2% | 47.0% | 53.3% | 36.4% |
| Net interest income | −$5.4M | — | — | — | — |
| Gross margin | 74.9% | 71.3% | 69.6% | 75.3% | 75.1% |
| Operating margin | 2.2% | 2.2% | 0.3% | 4.4% | 11.2% |
| Net income | −$18.0M | −$14.1M | −$24.4M | −$17.5M | −$5.1M |
| Net margin | −24.8% | −15.9% | −18.7% | −8.8% | −1.9% |
| Diluted EPS | −$0.69 | −$0.51 | −$0.75 | −$0.49 | −$0.14 |
| Cash | |||||
| Cash from operations | $5.1M | $1.7M | $3.8M | −$22.2M | $43.9M |
| Capital expenditure | $1.8M | $2.6M | $1.5M | $1.6M | $0.9M |
| Free cash flow | $3.3M | −$0.9M | $2.4M | −$23.8M | $43.0M |
| FCF margin | 4.5% | −1.0% | 1.8% | −11.9% | 15.8% |
| Share count change | 3.3% | 2.6% | 18.8% | 9.3% | 3.1% |
| Debt and strength | |||||
| Cash and short-term investments | $50.7M | $102M | $82.8M | $47.2M | $72.9M |
| Debt incl. finance leases | $103M | $152M | $247M | $263M | $250M |
| Shareholders' equity | $11.3M | $27.6M | $70.8M | $69.7M | $52.4M |
| Net debt / EBITDA | 15.7x | 14.7x | 83.6x | 20.2x | 5.5x |
| Current ratio | 6.2x | 6.3x | 2.8x | 2.1x | 2.2x |
| Interest coverage | 0.3x | 0.3x | 0.0x | 0.4x | 1.3x |
| Returns and quality | |||||
| Return on capital | 2.0% | 2.0% | 0.1% | 2.4% | 10.5% |
| Return on equity | −93.6% | −72.5% | −49.6% | −24.9% | −8.4% |
| Return on tangible equity | — | −398.1% | — | — | — |
| Piotroski F-score | 4 | 5 | 4 | 4 | 6 |
| Altman Z'' | 0.5 | 2.2 | 0.8 | 0.8 | 1.3 |
Insiders bought, 12 months
$0.5M
4 insiders
Insiders sold, 12 months
$9.6M
2 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Harrow, Inc. · HROW
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $28.95 a share, the company is worth $1.1B.
Source: SEC EDGAR XBRL filings (CIK 0001360214). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.